ATX-401 (Allay Therapeutics)

ATX-401 is a preclinical drug candidate being developed by Allay Therapeutics. It is built upon the company's proprietary drug-biopolymer platform, which is designed to provide localized, ultra-long-acting, non-opioid pain management. The technology involves a biodegradable polymer matrix that enables the controlled, sustained release of an analgesic agent directly at the site of administration. While the specific active pharmaceutical ingredient and the precise clinical indication for ATX-401 have not been publicly disclosed, the program is part of Allay's broader effort to provide long-term relief for post-surgical or chronic pain conditions.